Inicio
Cancer Research
|
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (2)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaPrognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation / Kenny Mauricio Gálvez Cárdenas ; González Artunduaga, Eliana Andrea ; Cruz Gutiérrez, Nelson Alirio ; Sandoval Álvarez, Simón
Título : Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; González Artunduaga, Eliana Andrea, Autor ; Cruz Gutiérrez, Nelson Alirio, Autor ; Sandoval Álvarez, Simón, Autor Fecha de publicación : 2025 Títulos uniformes : Cancer Research Idioma : Inglés (eng) Resumen : Introduction PET/CT assessment in newly diagnosed patients with multiple myeloma is a significant predictor of long-term clinical outcomes. Incorporating this imaging technique into a Bayesian analysis that addresses data gaps allows for more accurate prognostic estimates. This methodology enhances our understanding of the disease and guides informed clinical decisions, ultimately improving patient care. Objective This study aims to evaluate the prognostic value of PET/CT in newly diagnosed patients with multiple myeloma, using Bayesian analysis to manage missing data imputation. We seek to determine how PET/CT findings predict long-term clinical outcomes, thereby enhancing treatment personalization. Hypotheses: A positive PET/CT at diagnosis may correlate with poor prognosis, indicating lower survival rates and worse disease control. A negative PET/CT at diagnosis may be associated with better prognosis, suggesting higher treatment response rates and longer survival. Study Design An analytical study based on clinical and imaging data from PET/CT. Study Population Patients diagnosed with multiple myeloma between 2017 and 2024 at an institution in Medellín, Colombia, approved by the ethics committee of Pablo Tobón Hospital. Variables of Interest: Clinical Variables: Age, sex, type of treatment. PET/CT Variables: Positive (+), negative (-). Other Variables: Cytogenetics, Beta 2 Microglobulin (B2M), Bone Marrow Biopsy, Albumin, Hemoglobin. Outcome Variables: Overall Survival, Progression-Free Survival, Treatment Response. Data Imputation Methodology Using advanced R tools, including: MCMC: For parameter estimation despite incomplete data. SMC: To optimize sequential inferences and improve precision. Statistical Analysis: Kaplan-Meier survival curves for visualizing survival rates. Significance of covariates evaluated through 95% credibility intervals. Results The Bayesian model highlights PET/CT and cytogenetics as key outcome variables. A negative PET/CT correlates with better survival and more accurate treatment response prediction, while a positive PET/CT is linked to higher disease progression rates. Limitations Generalizability may be limited due to single-institution data. Missing data could introduce bias despite imputation methods. Short follow-up may restrict long-term outcome assessment. Variability in imaging protocols may affect result consistency. Conclusions Prognostic Value of PET/CT: The study indicates that PET/CT evaluation is a significant predictor of long-term outcomes in multiple myeloma. A negative PET/CT is linked to better prognosis and treatment response. Clinical Decision Making: Integrating Bayesian analysis and data imputation into PET/CT assessment enhances prognostic accuracy, providing clinicians with valuable insights for personalized treatment and optimized patient care. Citation Format Eliana Andrea González Artunduaga, Nelson Alirio Cruz Gutiérrez, Simón Sandoval Álvarez, Kenny Mauricio Gálvez Cárdenas. Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4516. Mención de responsabilidad : Eliana Andrea González Artunduaga; Nelson Alirio Cruz Gutiérrez; Simón Sandoval Álvarez; Kenny Mauricio Gálvez Cárdenas Referencia : Cancer Res (2025) 85 (8_Supplement_1): 4516. DOI (Digital Object Identifier) : 10.1158/1538-7445.AM2025-4516 Derechos de uso : CC BY-NC-ND En línea : https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4516/757005 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; González Artunduaga, Eliana Andrea, Autor ; Cruz Gutiérrez, Nelson Alirio, Autor ; Sandoval Álvarez, Simón, Autor . - 2025.
Obra : Cancer Research
Idioma : Inglés (eng)
Resumen : Introduction PET/CT assessment in newly diagnosed patients with multiple myeloma is a significant predictor of long-term clinical outcomes. Incorporating this imaging technique into a Bayesian analysis that addresses data gaps allows for more accurate prognostic estimates. This methodology enhances our understanding of the disease and guides informed clinical decisions, ultimately improving patient care. Objective This study aims to evaluate the prognostic value of PET/CT in newly diagnosed patients with multiple myeloma, using Bayesian analysis to manage missing data imputation. We seek to determine how PET/CT findings predict long-term clinical outcomes, thereby enhancing treatment personalization. Hypotheses: A positive PET/CT at diagnosis may correlate with poor prognosis, indicating lower survival rates and worse disease control. A negative PET/CT at diagnosis may be associated with better prognosis, suggesting higher treatment response rates and longer survival. Study Design An analytical study based on clinical and imaging data from PET/CT. Study Population Patients diagnosed with multiple myeloma between 2017 and 2024 at an institution in Medellín, Colombia, approved by the ethics committee of Pablo Tobón Hospital. Variables of Interest: Clinical Variables: Age, sex, type of treatment. PET/CT Variables: Positive (+), negative (-). Other Variables: Cytogenetics, Beta 2 Microglobulin (B2M), Bone Marrow Biopsy, Albumin, Hemoglobin. Outcome Variables: Overall Survival, Progression-Free Survival, Treatment Response. Data Imputation Methodology Using advanced R tools, including: MCMC: For parameter estimation despite incomplete data. SMC: To optimize sequential inferences and improve precision. Statistical Analysis: Kaplan-Meier survival curves for visualizing survival rates. Significance of covariates evaluated through 95% credibility intervals. Results The Bayesian model highlights PET/CT and cytogenetics as key outcome variables. A negative PET/CT correlates with better survival and more accurate treatment response prediction, while a positive PET/CT is linked to higher disease progression rates. Limitations Generalizability may be limited due to single-institution data. Missing data could introduce bias despite imputation methods. Short follow-up may restrict long-term outcome assessment. Variability in imaging protocols may affect result consistency. Conclusions Prognostic Value of PET/CT: The study indicates that PET/CT evaluation is a significant predictor of long-term outcomes in multiple myeloma. A negative PET/CT is linked to better prognosis and treatment response. Clinical Decision Making: Integrating Bayesian analysis and data imputation into PET/CT assessment enhances prognostic accuracy, providing clinicians with valuable insights for personalized treatment and optimized patient care. Citation Format Eliana Andrea González Artunduaga, Nelson Alirio Cruz Gutiérrez, Simón Sandoval Álvarez, Kenny Mauricio Gálvez Cárdenas. Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4516. Mención de responsabilidad : Eliana Andrea González Artunduaga; Nelson Alirio Cruz Gutiérrez; Simón Sandoval Álvarez; Kenny Mauricio Gálvez Cárdenas Referencia : Cancer Res (2025) 85 (8_Supplement_1): 4516. DOI (Digital Object Identifier) : 10.1158/1538-7445.AM2025-4516 Derechos de uso : CC BY-NC-ND En línea : https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4516/757005 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002390 AC-2025-073 Archivo digital Producción Científica Artículos científicos Disponible
Título : Human epidermal growth factor receptor 2–positive breast cancer is associated with indigenous american ancestry in Latin American women Tipo de documento : documento electrónico Autores : Alejandro Vélez Hoyos, ; Jorge Hernando Donado Gómez, Fecha de publicación : 2020 Títulos uniformes : Cancer Research Idioma : Inglés (eng) Resumen : Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortality than non-Hispanic White women. Studies in U.S. Latinas and Latin American women have reported a high incidence of HER2 positive (+) tumors; however, the factors contributing to this observation are unknown. Genome-wide genotype data for 1,312 patients from the Peruvian Genetics and Genomics of Breast Cancer Study (PEGEN-BC) were used to estimate genetic ancestry. We tested the association between HER2 status and genetic ancestry using logistic and multinomial logistic regression models. Findings were replicated in 616 samples from Mexico and Colombia. Average Indigenous American (IA) ancestry differed by subtype. In multivariate models, the odds of having an HER2+ tumor increased by a factor of 1.20 with every 10% increase in IA ancestry proportion (95% CI, 1.07–1.35; P = 0.001). The association between HER2 status and IA ancestry was independently replicated in samples from Mexico and Colombia. Results suggest that the high prevalence of HER2+ tumors in Latinas could be due in part to the presence of population-specific genetic variant(s) affecting HER2 expression in breast cancer. Significance: The positive association between Indigenous American genetic ancestry and HER2+ breast cancer suggests that the high incidence of HER2+ subtypes in Latinas might be due to population and subtype-specific genetic risk variants. Mención de responsabilidad : Katie M. Marker, Valentina A. Zavala, Tatiana Vidaurre, Paul C. Lott, Jeannie Navarro Vásquez, Sandro Casavilca-Zambrano, Mónica Calderón, Julio E. Abugattas, Henry L. Gómez, Hugo A. Fuentes, Ruddy Liendo Picoaga, Jose M. Cotrina, Silvia P. Neciosup, Carlos A. Castañeda, Zaida Morante, Fernando Valencia, Javier Torres, Magdalena Echeverry, Mabel E. Bohórquez, Guadalupe Polanco-Echeverry, Ana P. Estrada-Florez, Silvia J. Serrano-Gómez, Jenny A. Carmona-Valencia, Isabel Alvarado-Cabrero, María Carolina Sanabria-Salas, Alejandro Velez, Jorge Donado, Sikai Song, Daniel Cherry, Lizeth I. Tamayo, Scott Huntsman, Donglei Hu, Roberto Ruiz-Cordero, Ronald Balassanian, Elad Ziv, Jovanny Zabaleta, Luis Carvajal-Carmona; COLUMBUS Consortium and Laura Fejerman Referencia : Cancer Res. 2020 May 1;80(9):1893-1901. DOI (Digital Object Identifier) : 10.1158/0008-5472.CAN-19-3659 PMID : 32245796 En línea : https://cancerres.aacrjournals.org/content/80/9/1893 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Human epidermal growth factor receptor 2–positive breast cancer is associated with indigenous american ancestry in Latin American women [documento electrónico] / Alejandro Vélez Hoyos, ; Jorge Hernando Donado Gómez, . - 2020.
Obra : Cancer Research
Idioma : Inglés (eng)
Resumen : Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortality than non-Hispanic White women. Studies in U.S. Latinas and Latin American women have reported a high incidence of HER2 positive (+) tumors; however, the factors contributing to this observation are unknown. Genome-wide genotype data for 1,312 patients from the Peruvian Genetics and Genomics of Breast Cancer Study (PEGEN-BC) were used to estimate genetic ancestry. We tested the association between HER2 status and genetic ancestry using logistic and multinomial logistic regression models. Findings were replicated in 616 samples from Mexico and Colombia. Average Indigenous American (IA) ancestry differed by subtype. In multivariate models, the odds of having an HER2+ tumor increased by a factor of 1.20 with every 10% increase in IA ancestry proportion (95% CI, 1.07–1.35; P = 0.001). The association between HER2 status and IA ancestry was independently replicated in samples from Mexico and Colombia. Results suggest that the high prevalence of HER2+ tumors in Latinas could be due in part to the presence of population-specific genetic variant(s) affecting HER2 expression in breast cancer. Significance: The positive association between Indigenous American genetic ancestry and HER2+ breast cancer suggests that the high incidence of HER2+ subtypes in Latinas might be due to population and subtype-specific genetic risk variants. Mención de responsabilidad : Katie M. Marker, Valentina A. Zavala, Tatiana Vidaurre, Paul C. Lott, Jeannie Navarro Vásquez, Sandro Casavilca-Zambrano, Mónica Calderón, Julio E. Abugattas, Henry L. Gómez, Hugo A. Fuentes, Ruddy Liendo Picoaga, Jose M. Cotrina, Silvia P. Neciosup, Carlos A. Castañeda, Zaida Morante, Fernando Valencia, Javier Torres, Magdalena Echeverry, Mabel E. Bohórquez, Guadalupe Polanco-Echeverry, Ana P. Estrada-Florez, Silvia J. Serrano-Gómez, Jenny A. Carmona-Valencia, Isabel Alvarado-Cabrero, María Carolina Sanabria-Salas, Alejandro Velez, Jorge Donado, Sikai Song, Daniel Cherry, Lizeth I. Tamayo, Scott Huntsman, Donglei Hu, Roberto Ruiz-Cordero, Ronald Balassanian, Elad Ziv, Jovanny Zabaleta, Luis Carvajal-Carmona; COLUMBUS Consortium and Laura Fejerman Referencia : Cancer Res. 2020 May 1;80(9):1893-1901. DOI (Digital Object Identifier) : 10.1158/0008-5472.CAN-19-3659 PMID : 32245796 En línea : https://cancerres.aacrjournals.org/content/80/9/1893 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001571 AC-2020-084 Archivo digital Producción Científica Artículos científicos Disponible
